![Biogen Inc](/common/images/company/N_BIIB.png)
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen also markets novel MS drugs Plegridy, Tysabri, Tecfidera, and Vume... Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen also markets novel MS drugs Plegridy, Tysabri, Tecfidera, and Vumerity. In Japan, Biogen's MS portfolio is co-promoted by Eisai. Hemophilia therapies Eloctate and Alprolix (partnered with SOBI) were spun off as part of Bioverativ in 2017. Biogen has several drug candidates in phase 3 trials in neurology and neurodegenerative diseases and has launched Spinraza with partner Ionis. Aduhelm was approved as the firm's first Alzheimer's disease therapy in June 2021. Show more
The Gross Law Firm Notifies Biogen Inc. Investors of a Class Action Lawsuit and Upcoming Deadline - BIIB PR Newswire NEW YORK, July 17, 2024 NEW YORK, July 17, 2024 /PRNewswire/ -- The Gross Law...
Biogen Inc Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - BIIB PR Newswire LOS ANGELES, July 16, 2024 LOS ANGELES, July 16, 2024 /PRNewswire/ -- The DJS...
Biogen Inc. Sued for Securities Law Violations - Investors Should Contact The Gross Law Firm for More Information - BIIB PR Newswire NEW YORK, July 12, 2024 NEW YORK, July 12, 2024 /PRNewswire/...
July 22, 2024 Deadline: Contact The Gross Law Firm to Join Class Action Suit Against BIIB PR Newswire NEW YORK, July 3, 2024 NEW YORK, July 3, 2024 /PRNewswire/ -- The Gross Law Firm issues the...
CAMBRIDGE, Mass., July 02, 2024 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) has completed the acquisition of Human Immunology Biosciences (HI-Bio™), a privately-held clinical-stage...
Nike (NYSE:NKE) – Nike shares fell 14.04% in pre-market trading. Nike exceeded fourth-quarter fiscal earnings estimates with adjusted earnings of $1.01 per share, but sales of $12.6 billion...
BIIB LAWSUIT ALERT: The Gross Law Firm Notifies Biogen Inc. Investors of a Class Action Lawsuit and Upcoming Deadline PR Newswire NEW YORK, June 28, 2024 NEW YORK, June 28, 2024 /PRNewswire/...
TOKYO and CAMBRIDGE, Mass., June 27, 2024 (GLOBE NEWSWIRE) -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge...
Class Action Filed Against Biogen Inc. (BIIB) Seeking Recovery for Investors - Contact The Gross Law Firm PR Newswire NEW YORK, June 25, 2024 NEW YORK, June 25, 2024 /PRNewswire/ -- The Gross Law...
Biogen Inc. Securities Fraud Class Action Lawsuit Pending: Contact The Gross Law Firm Before July 22, 2024 to Discuss Your Rights - BIIB PR Newswire NEW YORK, June 20, 2024 NEW YORK , June 20...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | -11.58 | -4.86595512228 | 237.98 | 238 | 220.81 | 1133312 | 226.08095415 | CS |
4 | -0.95 | -0.417857928304 | 227.35 | 238 | 220.02 | 964385 | 226.80584377 | CS |
12 | 25.18 | 12.5136666335 | 201.22 | 238 | 199.1 | 1021047 | 224.71709707 | CS |
26 | -20.56 | -8.32523485585 | 246.96 | 252.17 | 189.44 | 1139352 | 221.66855314 | CS |
52 | -49.77 | -18.0215084911 | 276.17 | 280.415 | 189.44 | 1087031 | 237.31058325 | CS |
156 | -96.68 | -29.9244769097 | 323.08 | 351.86 | 187.16 | 1151935 | 251.15344153 | CS |
260 | -6.46 | -2.77419908958 | 232.86 | 468.2499 | 187.16 | 1358775 | 270.25724402 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.